Dr Daniel Primavessy
Head of Quality Control/ Laboratory Head

About

Daniel Primavessy, PhD, studied Bioinformatics and Biotechnology at Saarland University (Saarbrücken, Germany) and received a PhD in Pharmaceutics from Philipps-University Marburg (Germany).

He worked for two years as a postdoc at Saarland University and in a contract research organisation focusing on pulmonary in vitro instruments. In 2021 Dr Primavessy joined Midas Pharma as Project Manager for innovations in the pharmaceutical industry and became Head of Quality Control and Head of the GMP laboratory in 2024.

Contributions

INJECTION

COMPREHENSIVE TESTING PROVES DESIGN CONCEPT OF NOVEL AUTOINJECTOR PLATFORM

Farid Seddighi, Sigrid Saaler-Reinhardt and Daniel Primavessy discuss the critical importance of testing at an early stage of medical device development, presenting an overview of the results that confirm the technical performance and usability of the novel Gx Inbeneo^® autoinjector.

More contributions

INJECTION

A NOVEL INSTRUMENT TO STREAMLINE COMBINATION PRODUCT DEVELOPMENT

Daniel Primavessy, Sigrid Saaler-Reinhardt, Katarzyna Maksymowicz and Marie Stockton introduce the Gx Inbeneo^® platform simulator. This tool supports pharmaceutical companies in bridging formulation and medical device development processes, reducing time to market for patient-centric combination products.

INJECTION

GX INBENEO^® – DEVELOPING AN AUTOINJECTOR THAT RESPONDS TO THE CHALLENGES OF BIOLOGICS

Daniel Primavessy, Sigrid Saaler-Reinhardt, Katarzyna Maksymowicz and Marie Stockton, Marketing Manager discuss how the Gx Inbeneo^® autoinjector from Gerresheimer was purpose designed to provide an effective, easy-to-use solution for the subcutaneous self-administration of sensitive biopharmaceuticals.